OSE Immunotherapeutics - Lusvertikimab progressing on multiple fronts
OSE has announced that Lusvertikimab (or OSE-127), the company’s most advanced asset in the immuno-inflammation space, has received a positive...
241 Views
OSE Immunotherapeutics - US patent to bolster Tedopi’s product portfolio
OSE Immunotherapeutics has announced that Tedopi, the company’s lead cancer vaccine candidate, has been granted a new patent by the United States...
357 Views
OSE Immunotherapeutics - New diagnostic test to support Tedopi trial
OSE Immunotherapeutics (OSE) has received €1.5m in non-dilutive funding from Bpifrance (a French public sector investment bank) to develop a...
107 Views
OSE Immunotherapeutics - Milestones anticipated throughout FY23
OSE Immunotherapeutics has announced its FY22 results, providing financial and operational updates as the company continues to advance its key...
190 Views
OSE Immunotherapeutics - Encouraging safety data for OSE-127
OSE Immunotherapeutics has announced that the data from its earlier Phase I study for OSE-127/S95011, initially released in 2019, has been...
213 Views